{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T22:17:28Z","timestamp":1790979448563,"version":"4.1.0"},"reference-count":39,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2010,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Agomelatine (Valdoxan\u00ae) is licensed by the European Medicines Agency for the treatment of major depressive episodes in adults. The objective of this review was to consider how the drug should be used in clinical practice in particular starting, stopping and switching to and from the drug.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The existing clinical evidence was reviewed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Data suggest that when switching to agomelatine from other antidepressants consideration should be given to tapering the previous antidepressant in order to minimize the risk of the original drug causing discontinuation\/withdrawal symptoms. The risk of pharmacological interactions between most antidepressants and agomelatine is low and so tapering the previous antidepressant can usually be done after agomelatine has been started. An exception is fluvoxamine which should not be concurrently prescribed with agomelatine. As agomelatine appears to cause no significant discontinuation symptoms, it can probably be stopped abruptly when treatment is completed or when switching to another antidepressant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>While this guidance may change as clinical evidence and experience grows, currently agomelatine appears to have a good tolerability profile and is relatively easy to use, though prescribers should note the requirement to conduct liver function tests (LFTs) in accordance with the Summary of Product Characteristics (SPC). Copyright \u00a9 2010 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hup.1094","type":"journal-article","created":{"date-parts":[[2010,3,2]],"date-time":"2010-03-02T01:03:56Z","timestamp":1267491836000},"page":"95-102","source":"Crossref","is-referenced-by-count":41,"title":["The use of antidepressants in clinical practice: focus on agomelatine"],"prefix":"10.1002","volume":"25","author":[{"given":"R. H.","family":"McAllister\u2010Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. S.","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. M.","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bazire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,3]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107088441"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145705006358"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2005.11.025"},{"key":"e_1_2_1_5_1","first-page":"205","volume-title":"Psychotropic Drug Directory","author":"Bazire S","year":"2009"},{"key":"e_1_2_1_6_1","volume-title":"British Medical Association and Royal Pharmaceutical Society of Great Britain, Section 4.3. Antidepressant Drugs: Withdrawal","author":"British National Formulary","year":"2009"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145708009255"},{"key":"e_1_2_1_8_1","first-page":"48","article-title":"Use of slow\u2010release melatonin in treatment\u2010resistant depression","volume":"25","author":"Dalton EJ","year":"2000","journal-title":"J Psychiatry Neurosci"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/dtb.1999.37749"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2006.02.013"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.yic.0000277958.83475.d5"},{"key":"e_1_2_1_12_1","unstructured":"European Medicines Agency.2008.CHMP Assessment for Valdoxan London 20 November 2008 Doc. Ref.: EMEA\/655251\/2008."},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.16.12.1999"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04548"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1192\/apt.bp.105.001966"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0447.2000.102006466.x"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2004.06.003"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2007.tb01282.x"},{"issue":"1","key":"e_1_2_1_19_1","first-page":"193","article-title":"Effect of agomelatine on rest\u2010activity cycle in patients with major depressive disorder compared to sertraline","volume":"11","author":"Kasper S","year":"2008","journal-title":"Int J Neuropsychopharmacol"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n0812"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2005.09.002"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(99)00052-4"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n1112"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200209000-00004"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2007.01.011"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.4.3.281"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(98)00078-1"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.051797"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e3280c56b13"},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199300830-00008"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.yic.0000137184.64610.c8"},{"key":"e_1_2_1_32_1","first-page":"661","article-title":"Efficacy of agomelatine, a MT1\/MT2 receptor agonist with 5\u2010HT2C antagonistic properties, in major depressive disorder","volume":"10","author":"Oli\u00e9 JP","year":"2007","journal-title":"Int J Neuropsychopharmacol"},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v69n0113"},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199700321-00003"},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199902000-00013"},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(98)00126-7"},{"key":"e_1_2_1_37_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2869.1998.00121.x"},{"key":"e_1_2_1_38_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145707008000"},{"key":"e_1_2_1_39_1","unstructured":"Servier Laboratories Ltd. 2009. Valdoxan (agomelatine) Summary of Product Characteristics. Accessed 29th January 2010. (http:\/\/emc.medicines.org.uk\/medicine\/21830\/SPC\/Valdoxan\/)"},{"key":"e_1_2_1_40_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107081550"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.1094","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.1094","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T08:56:29Z","timestamp":1700556989000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.1094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["10.1002\/hup.1094"],"URL":"https:\/\/doi.org\/10.1002\/hup.1094","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}